NASDAQ · GRDX
Healthcare · Biotechnology
$2.86
Down-$0.11 (-3.70%)
Updated Sep 12, 2026, 11:29 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GRDX closed at $2.86 after 20 trading sessions, down 31.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.95 | $3.20 | $2.85 | $2.86 | 134.16K |
| Sep 10, 2026 | $3.01 | $3.29 | $2.94 | $2.97 | 69.37K |
| Sep 9, 2026 | $3.19 | $3.44 | $3.02 | $3.02 | 55.52K |
| Sep 8, 2026 | $3.18 | $3.38 | $3.135 | $3.20 | 58.71K |
| Sep 4, 2026 | $3.05 | $3.46 | $3.05 | $3.25 | 84.6K |
| Sep 3, 2026 | $3.50 | $3.50 | $2.81 | $2.97 | 213.41K |
| Sep 2, 2026 | $3.68 | $3.93 | $3.46 | $3.46 | 110.91K |
| Sep 1, 2026 | $3.70 | $3.72 | $3.5586 | $3.58 | 20.96K |
| Aug 31, 2026 | $3.83 | $4.19 | $3.69 | $3.72 | 40.91K |
| Aug 28, 2026 | $3.97 | $4.14 | $3.79 | $3.961 | 205.16K |
| Aug 27, 2026 | $4.00 | $4.13 | $3.8402 | $4.01 | 135.86K |
| Aug 26, 2026 | $4.01 | $4.18 | $3.81 | $4.04 | 303.24K |
| Aug 25, 2026 | $3.80 | $4.17 | $3.66 | $4.06 | 145.56K |
| Aug 24, 2026 | $3.375 | $3.79 | $3.30 | $3.65 | 151.95K |
| Aug 21, 2026 | $3.74 | $4.00 | $3.34 | $3.569 | 158.9K |
| Aug 20, 2026 | $3.99 | $3.99 | $3.67 | $3.75 | 126.65K |
| Aug 19, 2026 | $3.95 | $4.11 | $3.55 | $3.85 | 77.32K |
| Aug 18, 2026 | $3.95 | $4.24 | $3.80 | $3.89 | 177.73K |
| Aug 17, 2026 | $4.17 | $4.24 | $3.915 | $3.95 | 77.37K |
| Aug 14, 2026 | $4.00 | $4.25 | $3.67 | $4.17 | 311.58K |
The latest Smart Investors Daily articles mentioning GRDX.
GRDX research
Company profile and research snapshot.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 21, 2026
GridAI Technologies (NASDAQ:GRDX) reported quarterly losses of $(2.01) per share. This is a 773.91 percent decrease over losses of $(0.23) per share from the same period last year. The company reported $85.876 thousand
Benzinga · Feb 11, 2026
Benzinga · Feb 4, 2026
Yahoo · Jan 14, 2026
LOS ANGELES, CA - January 14, 2026 (NEWMEDIAWIRE) - GridAI Technologies (NASDAQ: GRDX) is aligning its platform with a structural shift in how the electric grid is operated as accelerating AI workloads, electrification, and distributed energy resourc...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GRDX.
